

1 **Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86,**
2 **JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya.**

3 Doreen Lugano ^{1*}, Bernadette Kutima ^{1*}, Makobu Kimani ¹, Antipa Sigilai ¹, John Gitonga ¹,
4 Angela Karani ¹, Donald Akech ¹, Boniface Karia ¹, Abdhahah K. Ziraba ⁴, Angela Maina ¹, Arnold
5 Lambisia ¹, Donwilliams Omuoyo ¹, Daisy Mugo ¹, Ruth Lucinde ¹, Joseph Newman ⁵, Dalan
6 Bailey ⁵, Eunice Nduati ¹, George Githinji ¹, Charles N. Agoti ¹, Philip Bejon ^{1,3}, J Anthony G
7 Scott ^{1,2}, Ambrose Agweyu ^{1,2}, Wangeci Kagucia ¹, George M Warimwe ^{1,3}, Charles Sande ¹,
8 Lynette I Ochola-Oyier ^{1*}, James Nyagwange ^{1*†}

9 ¹ KEMRI-Wellcome Trust Research Programme, P.O. Box 230 Kilifi, Kenya

10 ² Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical
11 Medicine, WC1E 7HT, Keppel Street, London, United Kingdom

12 ³ Nuffield Department of Medicine, Oxford University, OX3 7BN, Oxford, United Kingdom

13 ⁴ African Population and Health Research Center, APHRC Campus, Manga Close, Kitisuru
14 Nairobi, P.O. Box 10787, 00100 Nairobi, Kenya

15 ⁵ The Pirbright Institute, Ash Road, Woking, GU24 0NF, Surrey, United Kingdom

16 *Authors contributed equally

17 †Corresponding author at KEMRI-Wellcome Trust Research Programme P.O. Box 230 Kilifi.

18 Email: jnyagwange@kemri-wellcome.org

19

20

21

22 **Abstract**

23 Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a
24 key challenge to the control of COVID-19. The majority of these mutations mainly target the
25 spike protein, allowing the new variants to escape the immunity previously raised by vaccination
26 and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the
27 neutralizing capacity of antibodies against emerging variants of interest circulating between May
28 2023 and March 2024 using sera from representative samples of the Kenyan population. From
29 our genomics data, we identified the most prevalent Kenyan and global variants and performed
30 pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show
31 that antibodies from individuals in the general population in Kenya were less effective against
32 the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and
33 JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization
34 following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not
35 neutralize the omicron variants, suggesting that individuals were susceptible to infection by these
36 variants.

37 **Keywords:** SARS-CoV-2 variants, vaccination, neutralization, population immunity

38

39

40

41 Introduction

42 The emergence of new variants, recurring natural infection, vaccine efficacy, and
43 specificity and longevity of neutralizing antibodies are key variables determining long-term
44 control of coronavirus disease 2019 (COVID-19) ^{1,2}. Research efforts have focused on finding
45 interventions that can reduce infection and transmission while improving clinical outcomes of
46 COVID-19 in patients ³. A main strategy is the raising of protective neutralizing antibodies
47 (nAbs) in the host population through vaccination ⁴⁻⁷. Neutralizing antibodies bind to SARS-
48 CoV-2 structural proteins, especially the spike, inhibiting infection of host cells through the
49 ACE-2 receptor ⁸⁻¹⁰. However, the virus continues to mutate in the spike protein giving rise to
50 new variants. This makes it unclear to what extent neutralizing antibodies induced by earlier
51 exposure through natural infection and vaccination are protective to the emerging variants and
52 whether mono-variant multiple vaccine dosing improves this outcome.

53 The first vaccinations in Kenya began in adults in March 2021, and as of May 2022, the
54 Ministry of Health reported approximately 8.3 million fully vaccinated adults and 2.5 million
55 partially vaccinated adults ¹¹. This accounted for only 30.7% of the Kenyan adult population
56 being vaccinated and highlights issues with access, vaccine hesitancy due to religious and
57 cultural beliefs, and concerns over safety and efficacy ^{11,12}. Several studies report on vaccine
58 effectiveness in the rapid production of neutralizing antibodies against SARS-CoV-2 ^{1,2,8-10,13} and
59 similarly, natural infection leads to the development of wildtype and cross-protective nAbs
60 within the first two weeks after infection ^{1,2}.

61 Emerging SARS-CoV-2 variants have increased mutations targeted to the spike gene, that
62 lead to immune escape phenotypes ^{4,6}. Questions have been raised on whether ancestral strain
63 COVID-19 vaccines are sufficient to counter upcoming variants of concern and interest, and new

64 strategies on access and composition of vaccines are fast changing ^{4,14}. Alternatives such as
65 boosting with monovalent vaccines comprising more recent variants may improve neutralizing
66 antibody function and outcomes of COVID-19 in patients and the World Health Organization
67 Scientific Advisory Group of Experts (WHO-SAGE) recently recommended the development
68 and deployment of JN.1 spike-based vaccines ¹⁴⁻¹⁷.

69 Here we used genomic data to identify locally circulating variants in Kenya between May
70 2023 and March 2024 ^{18,19}. We evaluated the neutralizing capacity of antibodies from samples
71 collected from two health demographic surveillance systems in Kenya (n=58), for vaccine-
72 induced immunity against dominant variants EG.5.1, FY.4 ¹⁹, BA.2.86, JN.1, and JN.1.4. As a
73 comparator, we used natural wildtype infection samples (n=20) collected in 2020 at the onset of
74 the pandemic and confirmed to be PCR positive for SARS-CoV-2. We also assessed the effects
75 of different doses of vaccine, age, sex, and type of vaccine on antibody neutralizing titers.

76


77

78 **Results**


79 ***Circulating SARS-CoV-2 lineages between May 2023 and March 2024.***

80 We used genomic data to identify emerging variants of interest in Kenya and globally,
81 between May 2023 and March 2024²¹. The top circulating strains worldwide were XBB.1.5,
82 JN.1, JN.1.4, BA.2.86, EG.5.1.1, (Fig. 1A) whereas XBB.1.5, XBB.1.16, JN.1, JN.1.4, and
83 BA.2.86, were prominent in Europe (Fig. 1B). Kenya's leading strains were FY.4¹⁹, GE.1.2,
84 JN.1, JN.1.4, and JE.1.1 (Fig. 1C). We mapped 616 sequences from samples collected and
85 sequenced in Kenya in a phylogenetic tree. These samples were collected in 17 counties, with the
86 majority being from Nairobi (28%), Kilifi (20%), and Kiambu (13%) counties (Supplementary
87 Fig. 1). We show the predominance of strains FY.4¹⁹, GE.1.2, JN.1, JN.1.4, BQ.1.1, and
88 JE.1.1/KH.1 like variants (Fig. 1D). We performed pseudovirus neutralization assays on
89 circulating strains EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4. FY.4, JN.1, and JN.1.4 were
90 prevalent in Kenya during this period^{18,19}, while BA.2.86 and EG.5.1 were circulating in nearby
91 regions²⁵⁻²⁷.

92



D.



97

98 **Figure 1: SARS-CoV-2 lineage frequency (%) between May 2023 and March 2024.**

99 *This figure presents worldwide, European, and Kenyan SARS-CoV-2 lineage frequency % maps*
100 *from GISAID . A. Shows the lineage frequency % in all countries (n =775112) B. Shows the*
101 *lineage frequency % in Europe (n=232081). C. Shows the lineage frequency % in Kenya*
102 *(n=616). The legends in A, B, and C show the top circulating variants in each region within the*
103 *period of interest, with the colors corresponding to the frequency. D. Shows the phylogenetic*
104 *analysis of 616 sequences collected and sequenced from Kenya between May 2023 and March*
105 *2024. The legend shows the lineages corresponding to the colors on the tree.*

106 *An evaluation of neutralizing function against, wildtype, EG.5.1, FY.4, BA.2.86, JN.1, and*
 107 *JN.1.4, in population-representative samples*

108 **Table 1: Baseline characteristics of naturally infected and vaccinated cohort used in this**
 109 **study.** The table provides details of the sex, age, vaccination status, and type of vaccine in this
 110 cohort.

	AstraZeneca (n=30)	Pfizer (n=10)	Johnson & Johnson (n=10)	Moderna (n=6)	Mixed (n=2)	Wildtype Infected (n= 20)	Total (n=78)
Sex							
Male	15 (50%)	2 (20%)	5 (50%)	3 (50%)	0 (0%)	11 (55%)	36
Female	15 (50%)	8 (80%)	5 (50%)	3 (50%)	2 (100%)	9 (45%)	42
Age							
>18-60	24 (80%)	8 (80%)	8 (80%)	5 (83%)	2 (100%)	17 (85%)	64
>60	6 (20%)	2 (20%)	2 (20%)	1 (17%)	0 (0%)	3 (15%)	14
Vaccination							
1 dose	6 (20%)	4 (40%)	10 (100%)	0 (0%)	0 (0%)	0 (0%)	20
2 doses	14 (47%)	3 (30%)	0 (0%)	1 (17%)	1 (50%)	0 (0%)	19
3 doses	10 (33%)	3 (30%)	0 (0%)	5 (83%)	1 (50%)	0 (0%)	19


111

112 Inhibitory dilutions (ID₅₀) of sera from naturally infected (n=20) and vaccinated
 113 individuals (n=58) were used to determine neutralizing antibody function against EG.5.1, FY.4,
 114 BA.2.86, JN.1, and JN.1.4 pseudovirus variants. Compared to wildtype pseudovirus where
 115 (83%) 65/78 serum samples exhibited neutralization function, only 41/78 (53%) neutralized
 116 EG.5.1, 23/ 78 (29%) neutralized FY.4, 25/78 (32%) neutralized BA.2.86, 29/78 (37%)
 117 neutralized JN.1, and 31/78 (40%) neutralized JN.1.4 (Fig.2A-E). Furthermore, among the

118 positives we observed a consistent decline in neutralizing antibody titers against all strains with a
119 mean ID₅₀ of 1:613, 1:441, 1:576, 1:530, and 1:532 for EG.5.1, FY.4, BA.2.86, JN.1, and
120 JN.1.4, respectively, compared to 1:1155 in wildtype (Fig.2A-E). These differences in ID₅₀ of
121 the variants relative to wildtype were statistically significant (p-value <0.0001, Fig.2F).

122

123




124 **Figure 2: A comparison of inhibitory dilutions (ID_{50}) between wildtype and omicron variants**

125 **EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, in Kenyan population samples (n=78).** A. Represents
126 the log ID_{50} between wildtype and EG.5.1 where 41/78 in EG.5.1 showed neutralization. B.
127 Represents the log ID_{50} between wildtype and FY.4 where 23/78 samples showed neutralization.
128 C. Represents the log ID_{50} between wildtype and BA.2.86 where 25/78 samples showed
129 neutralization. D. Represents the log ID_{50} between wildtype and JN.1 where 29/78 samples
130 showed neutralization. E. Represents the log ID_{50} between wildtype and JN.1.4 where 31/78
131 samples showed neutralization. The numbers above each variant plot represent the mean ID_{50}
132 compared to wildtype. F. Shows the statistical analysis of ID_{50} between wildtype and each
133 variant. A statistical significance of $P < 0.0001$ (***) was recorded between wildtype and all
134 strains, based on Mann-Whitney tests. The sample colors represent SARS-CoV-2 variants where
135 red is wildtype, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is
136 JN.1.4. The dotted line represents the cut-off neutralization ID_{50} of 10^1 .

137 Next, we measured the escape from the existing humoral immunity by these variants after
138 natural infection with the wildtype variant and vaccination with different doses. Neutralization in
139 samples with wildtype natural infection showed that 18/20 (90%) individuals could neutralize the
140 wildtype but only 4/20 (20%) neutralized EG.5.1, 3/20 (15%) neutralized FY.4, 3/20 (15%)
141 neutralized BA.2.86, 3/20 (15%) neutralized JN.1, and 3/20 (15%) neutralized JN.1.4 (Fig.3A).
142 After one dose, there was increased neutralization of 12/20 (60%) in EG.5.1, 5/20 (25%) in
143 FY.4, 4/20 (20%) in BA.2.86, 8/20 (40%) in JN.1, 7/20 (35%) in JN.1.4, and 15/20 in wildtype
144 (75%). However, after three doses, there was significant decrease in neutralization function
145 against most omicron variants relative to two doses, where 12/19 (63%) individuals for EG.5.1,

146 3/19 (16%) for FY.4, 7/19 (37%) for BA.2.86, 7/19 (37%) for JN.1, and 8/19(42%) for JN.1.4
147 (Fig.3B).

148 We then examined whether the age of individuals who received one, two, or three doses
149 of the vaccine affected these findings. From the distribution of ages, we noted that the majority
150 of individuals who received two doses 14/20 (70%) and three doses 14/19 (74%) were above 50
151 years (Fig. 3C). Additionally, we determined whether days post-vaccination affected variances in
152 neutralization function. We found that 9/20 (45%) of individuals receiving two doses were
153 within 6 months of vaccination (180 days), whereas only 3/19 (15%) of individuals with three
154 doses were within this period, which could explain the decline in neutralization (Fig.3D). Lastly,
155 we evaluated the neutralization capacity between male and female participants and the type of
156 vaccine administered and observed no markable changes (Supplementary Fig. 2)



158 **Figure 3: Evaluation of naturally- acquired (n=20) and vaccine-induced immunity (n=58) in**
159 **Kenyan population samples. A & B. Shows neutralization (log ID₅₀) after natural infection**
160 **(n=20) or vaccination with one dose (n=20), two doses (n=19), and three doses (n=19). The**
161 **legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4,**
162 **green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by**
163 **Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***) . The dotted line**
164 **represents the cut-off neutralization ID₅₀ of 10¹. C. Represents the distribution of ID₅₀ based on**
165 **age between individuals administered with one, two, and three doses of vaccine. The dotted line**
166 **separates individuals below and above 50 years old. D. Shows the distribution based on days**
167 **post-vaccination with administering one, two, and three vaccine doses. The dotted line represents**
168 **a cut-off of 6 months after vaccination. C & D Circles represent one dose, boxes represent two**
169 **doses, and triangles represent three boxes.**

170 **Discussion**

171 The rapid mutation of the SARS-CoV-2 virus may lead to the emergence of new variants
172 that evade neutralization by pre-existing antibodies and have increased infectivity,
173 transmissibility, and pathogenicity²⁸⁻³². This study investigated neutralization as a correlate of
174 protection against emerging variants circulating between May 2023 and March 2024 in a subset
175 of the Kenya population. We used genomic data from Kenya¹⁸⁻²⁰, to identify variants circulating
176 during the study period and performed pseudoviruses neutralization assays.

177 Genomic data from samples collected in 17 counties in Kenya (Supplementary Fig. 1)
178 showed mostly similar lineage frequencies compared to other regions globally, but there were
179 occasional differences such as predominant circulation of FY.4 and GE.1.2 in the Kenyan
180 population only (Fig. 1 A-C)^{19,21}. We characterized EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4.

181 FY.4 was first reported in March of 2023 and was prevalent in Kenya, specifically in the coastal
182 region, with a Y451H mutation in the spike and P42L in the ORF3a (Fig. 1C-D)¹⁹. Functional
183 changes caused by Y451H remain unknown, but mutations on the ORF3a are linked to loss of
184 CD8+ T cell recognition¹⁹. EG.5.1 is a descendant of XBB.1.9.2 lineage which emerged in May
185 2023 and demonstrated substantial growth advantage over predecessor XBB lineages in Europe,
186 Asia, and North America²⁵. BA.2.86 was a variant of interest with more than 30 mutations on
187 the spike protein relative to ancestral strain BA.2 and had over 35 mutations compared to
188 XBB.1.5^{26,33}. It was first reported in mid-July 2023 and was highly prevalent in Israel, Europe,
189 and the US, and as of November 2023, it was detected in Kenya (Fig. 1A-D). Lastly, JN.1 and
190 JN.1.4 are sub-lineages of BA.2.86 and maintain the hallmark L455S amino acid change on the
191 spike and three key mutations in non-spike regions²⁵. These two later strains were the most
192 recent topmost circulating variants in many global regions and were reported to enhance immune
193 evasion properties and increase infectivity²⁵.

194 Surveillance of neutralizing capacity in a subset of population samples allows insights
195 into the general immunity and vaccine effectiveness, enabling the generation of better strategies
196 to mitigate future outbreaks^{15,34}. We observed that most wildtype-induced infections elicited
197 antibodies that could not neutralize the new variants. Interestingly, a few of these antibodies
198 showed neutralization capabilities against the emerging omicron variants, suggesting the
199 presence of cross-protective antibodies and presenting an opportunity for the isolation of cross-
200 protective monoclonal antibodies for therapeutic use, or inform the design of vaccines that
201 specifically induce cross-reactive antibodies.

202 We have demonstrated that both natural infection and vaccine-induced immunity from the
203 wildtype was neutralizing to the wildtype but non-neutralizing against the emerging omicron

204 variants. Although there was a substantial boost to neutralizing antibody titers against all new
205 variants after two doses, there was no evidence of further boosting after three doses, and possibly
206 even reductions against some variants. Similar observations have been reported in sera from 3-
207 dose mono-valent vaccinated individuals who exhibited non-neutralizing antibodies against
208 BA.2.86, and XBB variants²⁶. However, in our study cohort, 12/19 (63%) individuals with three
209 doses were above 50 years, and 16/19 (84%) were sampled about 9 months (287 days) post-
210 vaccination. Previously, it has been shown that for older individuals the level of protection
211 waned by more than 50 % after three or more doses within 6-9 months³³. Therefore, the reduced
212 neutralization after three doses observed in this study could have been confounded by the age of
213 the cohort, and the longer sampling frame post-vaccination, > 9 months. Nevertheless, the data
214 does not support repeated boosting as a strategy to generate cross-reactive antibodies.

215 Genomic surveillance of SARS-CoV-2 has greatly reduced in Kenya, hence all genomic
216 data in this study represents two-thirds of all geo-specified isolates came from two counties of
217 Kilifi and Nairobi, presenting a limitation of the study in generalization of the Kenya genomic
218 data. Another limitation of this study is the use of convenient cross-sectional samples which
219 implies the lack of follow up with participants to understand how pre and post-vaccination
220 infections could affect the neutralization capacity. Therefore, the data presumed as vaccine-
221 induced immunity could be caused by hybrid immunity and the differences could be driven by
222 infections by different variants. Some studies have suggested that vaccination and boosting by
223 the wildtype may result in immune imprinting and requirement for multiple boosting with
224 omicron based vaccines to achieve neutralization of the new variants^{16,35}. However, it is not
225 clear if natural infection could break the imprint to provide protective hybrid immunity. Also
226 unclear is the impact of such imprinting to countries such as Kenya which have majorly

227 administered mono-valent wildtype based vaccines and boosters. Nonetheless, mono-valent
228 studies using omicron and its emerging subvariant boosters are in progress and may provide
229 clarity in the future ¹⁴.

230 In conclusion, we demonstrate a decline in naturally acquired and vaccine-induced
231 antibody protection, with the emergence of new omicron variants in a subset of the Kenyan
232 population. This conclusion prompts the need for updated vaccine strategies in the country such
233 as boosting by vaccines with currently circulating variants, to counter immune escape as the
234 virus evolves, giving the population a chance to raise protective neutralizing antibodies to
235 circulating variants ^{14,15,16,34}. Although we have measured nAbs as a correlate of protection, other
236 arms of the immune system may also play a role in the protection against COVID-19, such as T-
237 cells ^{36,37}. Furthermore, the absence of nAbs may not necessarily mean absence of memory B-
238 cells which could be quickly mobilized to produce nAbs in case of an infection thereby
239 conferring protection ³⁸.

240 **Materials and Methods**

241 *Genomics data*

242 Genomics surveillance data from the Kenya Medical Research Institute Wellcome Trust
243 Research Programme (KWTRP), and other sequencing facilities in Kenya were used to
244 determine locally circulating variants between May 2023 and March 2024 ¹⁸⁻²⁰. The data
245 included samples collected from 17 Kenyan counties and sequenced in four Kenyan facilities,
246 KWTRP (57%), Kenya Medical Research Institute- Center for Disease Control and Prevention
247 (KEMRI-CDC) (39%), International Livestock Research Institute (ILRI) (2%), and National
248 Public Health Laboratory (NPHL) (1%). The majority of sequences were from the Nairobi (28%)

249 and Kilifi Health and Demographic Surveillance System (20%)¹⁸⁻²⁰ and Kiambu (13%)
250 (Supplementary Fig. 1). Percentage of SARS-CoV-2 lineage frequencies for circulating variants
251 in Kenya, Europe, and worldwide collected during the period of interest was based on data from
252 the Global Initiative on Sharing Avian Influenza Data (GISAID) as of 4th June 2024²¹. The
253 sequences collected and sequenced in Kenya during this period were downloaded in a multifasta
254 file and used to construct phylogenetic trees^{18,19}.

255 *Sample sets*

256 To evaluate population immunity against the emerging variants, we took advantage of
257 residual samples collected in the Kenya Multi-site Integrated Sero-surveillance study in the period
258 of September to December 2022 (n=30) and July to October 2023 (n=30)^{22,23}. This study was
259 approved by the Scientific Ethics Review Unit (SERU) under identification numbers 4085 and
260 4807. An inclusion criteria was the receipt of vaccination. We selected samples with well-
261 documented information on vaccination such as a vaccination certificate or a short message service
262 received after vaccination. As a comparator, we assayed plasma from 20 vaccine naïve SARS-
263 CoV-2 wildtype naturally exposed individuals with PCR-positive results and sampled ≥ 7 days after
264 their PCR-positive diagnosis¹⁷. The vaccinated post-pandemic panel consisted of 58 individuals
265 sampled from the Kilifi and Nairobi Health and Demographic Surveillance System (HDSS) site
266²². The HDSS participants who were confirmed for vaccination were further split according to the
267 number of doses received. A final classification of either one (n=20), two (n=19), or three doses
268 (n=19) was defined and used for assaying. Detailed demographic characteristics of participants
269 are shown in Table 1.

270 *Pseudovirus production and neutralization assay*

271 The pseudovirus production and assay validation have been described before ²⁴. Briefly, a
272 lentiviral expression system was used to produce wildtype and omicron sublineages, EG.5.1, FY.4,
273 BA.2.86, JN.1, and JN.1.4 pseudoviruses. Three plasmids, coding for the MLV-gag/pol backbone,
274 luciferase, and full-length spike protein of the different variants were co-transfected into HEK293T
275 cells using PEI (Polysciences, 24765-1) to produce a single round of infection competent
276 pseudoviruses. The media were changed 24hrs post-transfection and the pseudovirus harvested
277 72hrs post-transfection. The pseudoviruses were aliquoted and frozen for long-term storage. Virus
278 infectivity of the variants was determined by titration on HEK293T (hACE2-hTMPRSS2)-stable
279 cells and dilution of pseudoviruses giving >20,000RLU was selected for assaying. To test for
280 neutralization, 50 μ L of virus was immediately mixed with 50 μ L of serially diluted (2 \times) serum
281 and incubated for 1 h at 37°C. Following the incubation, 10,000 HEK293T (hACE2-hTMPRSS2)
282 cells/well (in 100 μ L of media) were directly added to the antibody-virus mixture. The plates were
283 then incubated at 37°C for 72 h. To check for neutralization, HEK293T (hACE2-hTMPRSS2) cells
284 were lysed using a lysis buffer (Promega, E2661). Luciferase intensity was then read on a
285 Luminometer with luciferase substrate according to the manufacturer's instructions (Promega,
286 E2650). The percentage of neutralization was calculated using the following equation: $100 \times (1 -$
287 $(\text{RLU of sample} - \text{average RLU of background}) / (\text{average RLU of virus only} - \text{average RLU of}$
288 $\text{background}))$, where the background was cell-only control. Additionally, as part of the assay
289 controls, a positive control of a pool of convalescent serum from 50 individuals with confirmed
290 COVID-19 and a negative control of a pool of pre-pandemic serum from 50 individuals were
291 included. To determine the ID50 value, a model of the dose-response curve was fit using the
292 sample dilution and the corresponding neutralization percentage.
293

294 **Statistical analysis**

295 Data analysis was run on R v4.3.2 and R Studio 2023.12.1. ID₅₀ significance was measured
296 using Student's t-test and Mann-Whitney tests, where significance was considered at p-value <
297 0.05 (*), p-value <0.001(**), and p-value <0.0001(***). The calculation of ID50 is as described
298 previously²⁴.

299

300 **References**

- 301 1. Altawalah, H. Antibody responses to natural sars-cov-2 infection or after covid-19 vaccination.
302 *Vaccines (Basel)* **9**, (2021).
- 303 2. Herzberg, J. *et al.* SARS-CoV-2-antibody response in health care workers after vaccination or
304 natural infection in a longitudinal observational study. *Vaccine* **40**, (2022).
- 305 3. Lotfi, M., Hamblin, M. R. & Rezaei, N. COVID-19: Transmission, prevention, and potential
306 therapeutic opportunities. *Clinica Chimica Acta* vol. 508 Preprint at
307 <https://doi.org/10.1016/j.cca.2020.05.044> (2020).
- 308 4. Changrob, S. *et al.* Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by
309 Antibodies Targeting Distinct Epitopes on Spike. *mBio* **12**, (2021).
- 310 5. Suryadevara, N. *et al.* Neutralizing and protective human monoclonal antibodies recognizing the
311 N-terminal domain of the SARS-CoV-2 spike protein. *Cell* **184**, (2021).
- 312 6. Liu, L. *et al.* Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
313 *Nature* **584**, (2020).
- 314 7. Uyoga, S. *et al.* Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.
315 *Science (1979)* **371**, (2021).

- 316 8. Ogbe, A. T. *et al.* ChAdOx1 nCoV-19 VACCINATION in PWH: IMMUNE RESPONSES to
317 SARS-CoV-2, VOCs, and HCoVs. *Top Antivir Med* **30**, (2022).
- 318 9. Chibwana, M. G. *et al.* AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive
319 antibody responses in Malawian adults previously infected with SARS-CoV-2. *BMC Med* **20**,
320 (2022).
- 321 10. Valleriani, F. *et al.* Neutralization of sars-cov-2 variants by serum from bnt162b2 vaccine
322 recipients. *Viruses* **13**, (2021).
- 323 11. *MINISTRY OF HEALTH KENYA COVID-19 VACCINATION PROGRAM-Daily Situation Report:*
324 *Current Status Total Doses Administered*; accessed on June 18, 2024.
- 325 12. Nasimiyu, C. *et al.* Near-Complete SARS-CoV-2 Seroprevalence among Rural and Urban
326 Kenyans despite Significant Vaccine Hesitancy and Refusal. *Vaccines (Basel)* **11**, (2023).
- 327 13. Bates, T. A. *et al.* Vaccination before or after SARS-CoV-2 infection leads to robust humoral
328 response and antibodies that effectively neutralize variants. *Sci Immunol* **7**, (2022).
- 329 14. WHO: Statement on the antigen composition of COVID-19 vaccines. [Statement on the antigen
330 composition of COVID-19 vaccines \(who.int\)](https://www.who.int/news-room/feature-stories/2022/06/20220620-who-statement-on-the-antigen-composition-of-covid-19-vaccines); accessed on June 18, 2024.
- 331 15. Abdoli, A., Jamshidi, H., Taqavian, M., Baghal, M. L. & Jalili, H. Omicron-specific and bivalent
332 omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model. *Sci
333 Rep* **14**, (2024).
- 334 16. Cerqueira-Silva, T., Boaventura, V. S. & Barral-Netto, M. Effectiveness of monovalent and
335 bivalent COVID-19 vaccines. *The Lancet Infectious Diseases* vol. 23 Preprint at
336 [https://doi.org/10.1016/S1473-3099\(23\)00379-1](https://doi.org/10.1016/S1473-3099(23)00379-1) (2023).

- 337 17. Widyasari, K., Jang, J., Kang, T. & Kim, S. Effectiveness of Bivalent Omicron-Containing Booster
338 Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-
339 CoV-2 Infection. *Viruses* **15**, (2023).
- 340 18. Lambisia, A. W. *et al.* Detection of a SARS-CoV-2 Beta-like variant in coastal Kenya after more
341 than a year of disappearance. *Wellcome Open Res* **8**, (2023).
- 342 19. Mwangi, M. J. *et al.* New SARS-CoV-2 Omicron Variant with Spike Protein Mutation Y451H,
343 Kilifi, Kenya, March-May 2023. *Emerg Infect Dis* **29**, (2023).
- 344 20. Githinji, G. *et al.* The genomic epidemiology of SARS-CoV-2 variants of concern in Kenya.
345 *medRxiv* (2022).
- 346 21. Khare, S. *et al.* GISAID's Role in Pandemic Response. *China CDC Wkly* **3**, (2021).
- 347 22. Kagucia, E. W. *et al.* SARS-CoV-2 seroprevalence and implications for population immunity:
348 Evidence from two Health and Demographic Surveillance System sites in Kenya, February–
349 December 2022. *Influenza Other Respir Viruses* **17**, (2023).
- 350 23. Kagucia, E. W. *et al.* Profile: The Kenya Multi-Site Serosurveillance (KEMIS) collaboration.
351 *Gates Open Res* **8**, 60 (2024).
- 352 24. Nyagwange, J. *et al.* Serum immunoglobulin G and mucosal immunoglobulin A antibodies from
353 prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. *International*
354 *Journal of Infectious Diseases* **127**, (2023).
- 355 25. Uraki, R. *et al.* Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. *Cell*
356 *Rep* **42**, (2023).
- 357 26. Qu, P. *et al.* Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip
358 variants. *Cell* **187**, 585-595.e6 (2024).

- 359 27. Planas, D. *et al.* Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages
360 combining increased fitness and antibody evasion. *Nat Commun* **15**, (2024).
- 361 28. Shah, M. & Woo, H. G. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger
362 Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies. *Front*
363 *Immunol* **12**, (2022).
- 364 29. Tang, H. *et al.* Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the
365 host. *Signal Transduction and Targeted Therapy* vol. 8 Preprint at [https://doi.org/10.1038/s41392-](https://doi.org/10.1038/s41392-023-01449-w)
366 [023-01449-w](https://doi.org/10.1038/s41392-023-01449-w) (2023).
- 367 30. Magazine, N. *et al.* Mutations and Evolution of the SARS-CoV-2 Spike Protein. *Viruses* vol. 14
368 Preprint at <https://doi.org/10.3390/v14030640> (2022).
- 369 31. Jary, A. *et al.* Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or
370 Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies. *Viruses* **14**,
371 (2022).
- 372 32. Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews*
373 *Microbiology* vol. 19 Preprint at <https://doi.org/10.1038/s41579-021-00573-0> (2021).
- 374 33. Cui, Z. *et al.* Structural and functional characterizations of infectivity and immune evasion of
375 SARS-CoV-2 Omicron. *Cell* **185**, (2022).
- 376 34. Scheaffer, S. M. *et al.* Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization
377 and protect against the BA.5 Omicron variant in mice. *Nat Med* **29**, (2023).
- 378 35. Yisimayi, A. *et al.* Repeated Omicron exposures override ancestral SARS-CoV-2 immune
379 imprinting. *Nature* **625**, (2024).
- 380 36. Kinoshita, H. *et al.* Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with
381 Antibody Deficiency. *J Clin Immunol* **41**, (2021).

382 37. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild
383 COVID-19. *Cell* **183**, (2020).

384 38. Zhang, Z. *et al.* Humoral and cellular immune memory to four COVID-19 vaccines. *Cell* **185**,
385 (2022).

386

387 **Acknowledgments**

388 We thank all the sample donors for their contribution to the research. We also acknowledge all
389 GISAID data contributors whose genomic sequences and metadata this work is based on.

390 **Funding**

391 This research was funded in whole or in part by the Wellcome Trust (grants
392 226141/Z/22/Z, 226130/Z/22/Z, 227131/Z/23/Z & 227131/B/23/Z 226141/Z/22/Z and
393 226002/A/22/Z), MRC (MR/W005611/1, MR/Y004205/1), BBSRC (BBS/E/I/COV07001,
394 BBS/E/I/00007031) and Bill and Melinda Gates Foundation (INV-039626). For the purpose of
395 Open Access, the author has applied a CC-BY public copyright license to any author accepted
396 manuscript version arising from this submission.

397 **Author contribution**

398 Conceptualization and methodology: JN. Investigation: BK, JN, DL, MK, AS, JG, AK, DA, BK,
399 AM, AL, DO, RL, JN. Formal analysis: JN, DL, BK, GG. Resources and funding acquisition:
400 JN, IO, DB, GG, CS, EN. Writing, original draft preparation: DL, JN, BK. Writing, review and
401 editing: all authors

402 **Conflicts of interest**

403 The authors report no conflicts of interest

404 **Ethics declaration**

405 This study was approved by the Scientific and Ethics Review Unit (SERU) of the Kenya Medical
406 Research Institute (SERU ID: 4085 and 4807). Written informed consent was obtained from
407 participants for the collection, storage, and further use of their sample sets in the research.

408 **Figure Legends**

409 **Figure 1: SARS-CoV-2 lineage frequency (%) between May 2023 and March 2024.** This
410 figure presents worldwide, European, and Kenyan SARS-CoV-2 lineage frequency % maps from
411 GISAID . A. Shows the lineage frequency % in all countries (n =775112) B. Shows the lineage
412 frequency % in Europe (n=232081). C. Shows the lineage frequency % in Kenya (n=616). The
413 legends in A, B, and C show the top circulating variants in each region within the period of
414 interest, with the colors corresponding to the frequency. D. Shows the phylogenetic analysis of
415 616 sequences collected and sequenced from Kenya between May 2023 and March 2024. The
416 legend shows the lineages corresponding to the colors on the tree.

417 **Figure 2: A comparison of inhibitory dilutions (ID₅₀) between wildtype and omicron**
418 **variants EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, in Kenyan population samples (n=78).** A.
419 Represents the log ID₅₀ between wildtype and EG.5.1 where 41/78 in EG.5.1 showed
420 neutralization. B. Represents the log ID₅₀ between wildtype and FY.4 where 23/78 samples
421 showed neutralization. C. Represents the log ID₅₀ between wildtype and BA.2.86 where 25/78

422 samples showed neutralization. D. Represents the log ID₅₀ between wildtype and JN.1 where
423 29/78 samples showed neutralization. E. Represents the log ID₅₀ between wildtype and JN.1.4
424 where 31/78 samples showed neutralization. The numbers above each variant plot represent the
425 mean ID₅₀ compared to wildtype. F. Shows the statistical analysis of ID₅₀ between wildtype and
426 each variant. A statistical significance of P< 0.0001 (***) was recorded between wildtype and all
427 strains, based on Mann-Whitney tests. The sample colors represent SARS-CoV-2 variants where
428 red is wildtype, blue is EG.5.1, yellow is FY.4, green is BA.2.86, orange is JN.1, and brown is
429 JN.1.4. The dotted line represents the cut-off neutralization ID₅₀ of 10¹.

430 **Figure 3: Evaluation of naturally- acquired (n=20) and vaccine-induced immunity (n=58) in**

431 **Kenyan population samples.** A & B. Shows neutralization (log ID₅₀) after natural infection
432 (n=20) or vaccination with one dose (n=20), two doses (n=19), and three doses (n=19). The
433 legend represents SARS-CoV-2 variants where red is Wuhan, blue is EG.5.1, yellow is FY.4,
434 green is BA.2.86, orange is JN.1, and brown is JN.1.4. Statistical significance was determined by
435 Mann-Whitney tests where P<0.05 (*), P<0.001 (**), and P<0.0001 (***). The dotted line
436 represents the cut-off neutralization ID₅₀ of 10¹. C. Represents the distribution of ID₅₀ based on
437 age between individuals administered with one, two, and three doses of vaccine. The dotted line
438 separates individuals below and above 50 years old. D. Shows the distribution based on days
439 post-vaccination with administering one, two, and three vaccine doses. The dotted line represents
440 a cut-off of 6 months after vaccination. C & D Circles represent one dose, boxes represent two
441 doses, and triangles represent three boxes.

442

443

444 **Tables**

445 **Table 1: Baseline characteristics of naturally infected and vaccinated cohort used in this**
 446 **study.** The table provides details of the sex, age, vaccination status, and type of vaccine in this
 447 cohort.

	AstraZeneca (n=30)	Pfizer (n=10)	Johnson & Johnson (n=10)	Moderna (n=6)	Mixed (n=2)	Wildtype Infected (n= 20)	Total (n=78)
Sex							
Male	15 (50%)	2 (25%)	5 (50%)	3 (50%)	0 (0%)	11 (55%)	36
Female	15 (50%)	8 (75%)	5 (50%)	3 (50%)	2 (100%)	9 (45%)	42
Age							
>18-60	24 (81%)	8 (75%)	8 (80%)	5 (75%)	2 (100%)	17 (85%)	64
>60	6 (19%)	2 (25%)	2 (20%)	1 (25%)	0 (0%)	3 (15%)	14
Vaccination							
1 dose	6 (23%)	4 (38%)	10 (100%)	0 (0%)	0 (0%)	0 (0%)	20
2 doses	14 (50%)	3 (38%)	0 (0%)	1 (25%)	1 (50%)	0 (0%)	19
3 doses	10 (27%)	3 (24%)	0 (0%)	5 (75%)	1 (50%)	0 (0%)	19

448